For patients with elevated intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT)

Start with ZIOPTAN

Richard, 65

Diagnosed with OAG

Full-time accountant

  • IOP:
  • 26 mmHG
  • Humphrey visual fields:
  • OD Normal, OS Inferior arcuate defect, temporal scotoma
  • Cup-to-disk ratio:
  • 0.5 OD, 0.7 OS
  • Family history:
  • Parents with hypertension
  • Previous ophthalmic Tx:
  • None

ZIOPTAN is only approved to lower elevated IOP, and it does not have any effect on any other signs of OAG or OHT.

LISA, 45

Diagnosed with OHT

Part-time sales clerk, mother of 3 young children

  • IOP:
  • 23 mmHg
  • Humphrey visual fields:
  • OD Normal, OS Normal
  • Central corneal thickness:
  • 480 μm OU
  • Family history:
  • Father with OAG
  • Previous ophthalmic Tx:
  • None

OD=oculus dexter; OS=oculus sinister; OU=oculi uterque.

ZIOPTAN is indicated for reducing elevated IOP in patients with OAG or OHT.

Select Important Safety Information

ZIOPTAN should be used with caution in patients with active intraocular inflammation (e.g., iritis/uveitis) because the inflammation may be exacerbated.

Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin F2α analogs. ZIOPTAN should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.

In clinical trials of patients receiving either preservative-containing or preservative-free ZIOPTAN, the most common pooled adverse reaction observed was conjunctival hyperemia, which was reported in a range of 4% to 20% of patients.

There are no adequate and well-controlled studies in pregnant women. ZIOPTAN should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus.

It is not known whether ZIOPTAN or the metabolites of ZIOPTAN are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ZIOPTAN is administered to a nursing woman.

Use in pediatric patients is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use.

Before prescribing ZIOPTAN, please read the Prescribing Information.